欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
OCI-Aml-3人急性髓性白血病细胞 (STR鉴定)
英文名:OCI-Aml-3
货号:ZQ0580
价格:¥1800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

OCI-Aml-3人急性髓性白血病细胞 (STR鉴定)

¥1800.00
+

OCI-Aml-3急性淋巴细胞专用培养基

¥650.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2450
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

OCI-Aml-3人急性髓性白血病细胞

货号

ZQ0580

产品介绍

OCI-Aml-3是一种人急性髓性白血病细胞系,是从1987年诊断为急性髓细胞性白血病(AML FAB M4)的57岁男性的外周血中建立的。细胞携带NPM1基因突变(A型)和DNMT3A R882C突变。广泛用于急性髓性白血病的研究,包括药物筛选、细胞信号传导研究、白血病的分子机制研究等。例如:OCI-Aml-3细胞系在药物筛选中的应用主要包括以下几个方面:白血病药物靶点的鉴定、药物敏感性测试、药物组合效应研究、药物耐药性研究、药物开发和前临床研究、药物作用机制研究等。这些应用展示了OCI-Aml-3细胞系在AML药物筛选和研究中的广泛价值,为开发新的治疗策略和药物提供了重要的实验工具。

种属

性别/年龄

男/57岁 

组织

外周血

疾病

急性髓性白血病

细胞类型

肿瘤细胞 

形态学

单个,主要是圆形细胞

生长方式

悬浮

倍增时间

大约28~40小时

培养基和添加剂

RPMI-1640基础培养基(中乔新舟 货号:ZQ-200+20%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0580

生物安全等级

BSL-1

STR位点信息

Amelogenin:X;
CSF1PO: 11,12;
D2S1338:17,21;
D3S1358:16;
D5S818: 11,13;
D7S820: 9,10;
D8S1179:10,12;
D13S317:8,13;
D16S539:11,13;
D18S51: 12,18;
D19S433:15,17;
D21S11: 29,30;
FGA:22;
Penta D: 12,13;
Penta E: 11,13;
TH01: 8,9.3 (DSMZ=ACC-582);
             8,10 (Cosmic-CLP=1290455; PubMed=25877200);
TPOX:8,11;
vWA:17,18;

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

DSMZ; ACC-582

供应限制

仅供科研使用

货号

ZQ0580

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、PubMed=2538684
Wang C., Curtis J.E., Minden M.D., McCulloch E.A.
Expression of a retinoic acid receptor gene in myeloid leukemia cells.
Leukemia 3:264-269(1989)


2、PubMed=16079892; DOI=10.1038/sj.leu.2403899
Quentmeier H., Martelli M.P., Dirks W.G., Bolli N., Liso A., MacLeod R.A.F., Nicoletti I., Mannucci R., Pucciarini A., Bigerna B., Martelli M.F., Mecucci C., Drexler H.G., Falini B.
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
Leukemia 19:1760-1767(2005)


3、PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)


4、PubMed=21552520; DOI=10.1371/journal.pone.0019169
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A., Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)


5、PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


6、PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)


7、PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


8、PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


9、PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


10、PubMed=26434589; DOI=10.1038/onc.2015.359
Ferreira H.J., Heyn H., Vizoso M., Moutinho C., Vidal E., Gomez A., Martinez-Cardus A., Simo-Riudalbas L., Moran S., Jost E., Esteller M.
DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
Oncogene 35:3079-3082(2016)


11、PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


12、PubMed=28109323; DOI=10.1186/s13045-017-0396-0
Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A., Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M., Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
J. Hematol. Oncol. 10:26.1-26.5(2017)


13、PubMed=29491412; DOI=10.1038/s41388-018-0150-2
Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D., Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N., Gerstberger T., Zuber J., Savarese F., Kraut N.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene 37:2687-2701(2018)


14、PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)


15、PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)


16、PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


17、PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)


18、PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


19、PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)


20、PubMed=31739141; DOI=10.1016/j.leukres.2019.106270
Quentmeier H., Pommerenke C., Dirks W.G., Fahnrich S., Hauer V., Uphoff C.C., Zaborski M., Drexler H.G.
DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.
Leuk. Res. 88:106270.1-106270.3(2020)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号